A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Trial Profile

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Avatrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms Adapt I
  • Sponsors Dova Pharmaceuticals; Eisai Inc
  • Most Recent Events

    • 10 Aug 2017 According to a Dova Pharmaceuticals media release, data from ADAPT-1 and ADAPT-2 trials has been accepted for presentation at the American Association for the Study of Liver Disease Annual Meeting
    • 19 May 2016 According to a PBM media release, this phase III study is conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration as a potential treatment for thrombocytopenia in patients with chronic liver disease undergoing an elective procedure.
    • 02 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials. gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top